Rna Editing News Today

Platform demonstrates robust in vivo editing capabilities reporting up to 70% editing of ACTB in the liver of non-human primates (NHPs) and miceFunctional effect demonstrated in mice in vivo via modulation of ANGPLT3 protein properties leading to favorable increase in LPL enzymatic activity and meaningful impact of biomarkersAdditional data to be presented throughout 2024, including in vitro and in vivo data for pipeline programs AX-0810 for Cholestatic diseases targeting NTCP and AX-1412 for Ca

Wave Life Sciences Ltd. (NASDAQ:WVE) Q3 2023 Earnings Call Transcript November 10, 2023 Operator: Good morning and welcome to Wave Life Sciences Third Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode. As a reminder, this call is being recorded and webcast. Now I’ll turn the call over […]

LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies today provided an update that its previously announced agreement to divest the Company’s late-stage ophthalmic assets to Laboratoires Théa S.A.S. (Théa) has been terminated. The completion of the transaction was conditional on Théa entering into employment agreements with a ...

A new study finds complexin is a key protein for regulating neural communication. New research finds neurons stochastically generated up to eight different versions of complexin release, which could vary how they communicate with other cells.

Wave Life Sciences Ltd. (NASDAQ:WVE) Q2 2023 Earnings Call Transcript August 6, 2023 Operator: Good morning, and welcome to the Wave Life Sciences Second Quarter 2023 Financial Results Conference Call. [Operator Instructions] As a reminder, this call is being recorded and webcast. I’ll now turn the call over to Kate Rausch, Vice President of Investor […]

Divestment of sepofarsen and ultevursen ophthalmic programs supports ProQR’s strategic focus on Axiomer® RNA editing platform technology and continued advancement of pipeline€129 M cash and cash equivalents as of June 30, 2023 providing runway into mid-2026 LEIDEN, Netherlands & CAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprieta...

When octopuses were exposed to cold water tanks, the researchers saw an increase in RNA editing.

Wistar Institute scientists uncover a new function of the ADAR1 enzyme, linking it to age-related diseases independent of RNA editing during aging.

Verve Therapeutics is trialing a gene-editing treatment with CRISPR to change the DNA in liver cells to lower LDL cholesterol.

As genetic engineering and DNA manipulation tools like CRISPR continue to advance, the distinction between what science ‘could’ and ‘should’ do becomes murkier.